Autoimmune haemolytic anaemia – diagnosis and treatment, including erythrocyte transfusions
Authors:
M. Lukášová 1; J. Procházková 2; A. Hluší 2
Authors‘ workplace:
Hemato-onkologická klinika Fakultní nemocnice Olomouc
1; Hemato-onkologická klinika, Lékařská fakulta Univerzity Palackého v Olomouci a Fakultní nemocnice Olomouc
2
Published in:
Transfuze Hematol. dnes,23, 2017, No. 1, p. 41-51.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Diagnosis of autoimmune haemolytic anaemia (AIHA) is usually quite straightforward. It is based on the clinical and laboratory presentation of haemolytic anaemia and serological detection of anti-erythrocyte autoantibodies, except for 5–10 % cases where detection of anti-erythrocyte autoantibodies using conventional methods is unsuccessful. However, treatment is more complicated, particularly the decision when to indicate splenectomy. Given the relative rarity of the disease, robust, prospective, randomized, comparative studies are lacking. When treating AIHA refractory to multiple treatment lines or the rare post-transplant autoimmune haemolytic anaemia, we have to rely on individual case reports.
KEY WORDS:
autoimmune haemolytic anaemia – diagnosis – treatment – warm autoimmune haemolytic anaemia – cold autoimmune haemolytic anaemia
Sources
1. Barros MM, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. Transfus Med Rev 2010; 24(3): 195–210.
2. Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3 + CD25 + CD4 + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212: 8-27.
3. Ward FJ, Hall AM, Cairns LS, et al. Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia. Blood 2008; 111: 680–687.
4. Ahmad E, Elgohary T, Ibrahim H. Naturally occurring regulatory T cells and interleukins 10 and 12 in the pathogenesis of idiopathic warm autoimmune hemolytic anemia. J Investig Allergol Clin Immunol 2011; 21: 297–304.
5. Xu L, Zhang T, Liu Z, Li Q, Xu Z, Ren T. Critical role of Th17 cells in development of autoimmune hemolytic anemia. Exp Hematol 2012; 40: 994–1004.
6. Raida L. Autoimunitní hemolytické anémie. In: Indrák K (ed.) Hematologie a transfuzní lékařství, Triton, 2014; 39–42.
7. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica 2014; 99(10): 1547–1554.
8. Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood 2014; 124: 2930–2936.
9. Jaime-Pérez JC, Rodríguez-Martínez M, Gómez-de-León A, Tarín--Arzaga L, Gómez-Almaguer D. Current approaches for the treatment of autoimmune hemolytic anemia. Arch Immunol Ther Exp (Warsz) 2013; 61: 385–395.
10. Písačka M. Autoimunitní hemolytické anémie. In: Řeháček V, Masopust J. a kol. Transfuzní lékařství, Grada, 2013; 144–151.
11. Čermák J. Anémie hemolytické indukované léky. In: Indrák K (ed.) Hematologie a transfuzní lékařství, Triton, 2014; 61–63.
12. Liesveld JL, Rowe JM, Lichtman MA. Variability of the erythrocyte response in autoimmune hemolytic anemias: analysis of 109 cases. Blood 1987; 69: 820–826.
13. Fattizzo B, Zaninoni A, Nesa F, et al. Lessons from very severe, refractory and fatal primary autoimmune hemolytic anemias. Am J Hematol 2015; 90: E149–151.
14. Bass GF, Tuscano ET, Tuscano JM. Diagnosis and classification of autoimmune hemolytic anemia. Autoimmun Rev 2014; 13: 560–564.
15. Arndt PA, Leger RM, Garratty G. Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies. Transfusion 2009; 49: 235–242.
16. Bartolmas T, Salama A. A dual antiglobulin test for the detection of weak or nonagglutinating immunoglobulin M warm autoantibodies. Transfusion 2010; 50:1131–1134.
17. Fayek MH, Saad AA, Eissa DG, Tawfik LM, Kamal G. Role of gel test and flow cytometry in diagnosis of Coombs‘ negative autoimmune haemolytic anaemia. Int J Lab Hematol. 2012; 34(3): 311–319.
18. Barcellini W, Zaninoni A, Imperiali FG, Zenella A, et al. Mitogen-stimulated DAT: a new method for the diagnosis of AIHA. Blood Transf 2003; 2: 127–136.
19. Thedsawad A, Taka O, Wanachiwanawin W. Development of flow cytometry for detection and quantitation of red cell bound immunoglobulin G in autoimmune hemolytic anemia with negative direct Coombs test. Asian Pac J Allergy Immunol 2011; 29(4): 364–367.
20. Meulenbroek EM, Haas M, Brouwer C, Folman C, Zeerleder SS, Wouters D. Complement deposition in autoimmune hemolytic anemia is a footprint for difficult-to-detect IgM autoantibodies. Haematologica 2015; 100(11): 1407–1414.
21. Jeong-Shi Lin, Tsung-Chi Hao, Jau-Yi Lyou, et al. Clinical application of a flow cytometric direct antiglobulin test. Transfusion 2009; 49: 1335–1346.
22. Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood 2013; 122: 1114–1121.
23. Berentsen S. How I manage cold agglutinin disease. Br J Haematol 2011; 153: 309–317.
24. Procházková J. Autoimunitní hemolytická anemie. In: Zadražil, Horák, Karásek Moderní farmakoterapie autoimunitních chorob, Maxdorf Jessenius, 2015; 333–337.
25. Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol 2013; 163: 393–399.
26. Dierickx D, Kentos A, Delannoy A. The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. Blood 2015; 125: 3223–3229.
27. Peñalver FJ, Alvarez-Larrán A, Díez-Martin JL, et al. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol 2010; 89: 1073–1080.
28. Maung SW, Leahy M, O’Leary HM, et al. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. Br J Haematol 2013; 163(1): 118–122.
29. Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood 2012; 119: 3691–3697.
30. Crowther M, Chan YL, Garbett IK, Lim W, Vickers MA, Crowther MA. Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. Blood 2011; 118: 4036–4040.
31. Arbach O, Funck R, Seibt F, Salama A. Erythropoietin may improve anemia in patients with autoimmune hemolytic anemia associated with reticulocytopenia. Transfus Med Hemother 2012; 39: 221–223.
32. Moyo VM, Smith D, Brodsky I, Crilley P, Jones RJ, Brodsky RA. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood 2002; 100: 704–706.
33. Berentsen S, Randen U, Vagan AM, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood 2010; 116: 3180–3184.
34. Shi J, Rose EL, Singh A, et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood 2014; 123: 4015–4022.
35. Wouters D, Stephan F, Strengers P, et al. C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia. Blood 2013; 121: 1242–1244.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2017 Issue 1
Most read in this issue
- Autoimmune haemolytic anaemia – diagnosis and treatment, including erythrocyte transfusions
- Modern therapy of acute myeloid leukaemia
- Experience with ruxolitinib in the treatment of myelofibrosis and polycythaemia vera at Czech haematological institutions
- Prevention and therapy of venous thromboembolism in cancer patients